BerandaADAP • NASDAQ
add
Adaptimmune Therapeutics PLC - ADR
$0,25
Setelah Jam Perdagangan Normal:(5,69%)+0,014
$0,26
Tutup: 12 Jun, 19.39.19 GMT-4 · USD · NASDAQ · Pernyataan Penyangkalan
Tutup sebelumnya
$0,27
Rentang hari
$0,25 - $0,27
Rentang tahun
$0,20 - $1,48
Kapitalisasi pasar
65,87Â jt USD
Volume Rata-Rata
1,27Â jt
Bursa utama
NASDAQ
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 7,28Â jt | 28,30% |
Biaya operasional | 21,62Â jt | 9,57% |
Laba bersih | -47,58Â jt | 1,89% |
Margin laba bersih | -653,18 | 23,54% |
Penghasilan per saham | -0,18 | 0,00% |
EBITDA | -41,60Â jt | 10,39% |
Tarif pajak efektif | -1,22% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 59,56Â jt | -58,54% |
Total aset | 158,07Â jt | -38,73% |
Total liabilitas | 195,50Â jt | -16,32% |
Total ekuitas | -37,43 jt | — |
Saham yang beredar | 265,05 jt | — |
Harga terhadap nilai buku | -1,81 | — |
Tingkat pengembalian aset | -54,54% | — |
Tingkat pengembalian modal | -226,39% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Mar 2025info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -47,58Â jt | 1,89% |
Kas dari operasi | -66,59Â jt | -108,43% |
Kas dari investasi | 41,15Â jt | 11.595,53% |
Kas dari pembiayaan | -25,32Â jt | -186,61% |
Perubahan kas bersih | -50,20Â jt | -1.338,87% |
Arus kas bebas | -46,77Â jt | -231,83% |
Tentang
Adaptimmune is a biopharmaceutical company that develops T cell therapies against cancer. The company was founded in 2008 in the UK with links to both Oxford University and the University of Pennsylvania. It has headquarters in Philadelphia and Milton Park. In August 2024, the US Food and Drug Administration granted accelerated approval to Adaptimmune's Tecelra, a therapy against a rare form of cancer. Tecelra is the first T cell therapy to be approved for use against a solid tumor. Wikipedia
Didirikan
2008
Situs
Karyawan
506
